Cyclin-Dependent Kinase Inhibitor p21
"Cyclin-Dependent Kinase Inhibitor p21" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclin-dependent kinase inhibitor that mediates TUMOR SUPPRESSOR PROTEIN P53-dependent CELL CYCLE arrest. p21 interacts with a range of CYCLIN-DEPENDENT KINASES and associates with PROLIFERATING CELL NUCLEAR ANTIGEN and CASPASE 3.
| Descriptor ID |
D050759
|
| MeSH Number(s) |
D12.644.360.225.500 D12.776.157.687.250 D12.776.167.187.500 D12.776.476.225.500 D12.776.624.776.355.500 D12.776.660.720.250
|
| Concept/Terms |
Cyclin-Dependent Kinase Inhibitor p21- Cyclin-Dependent Kinase Inhibitor p21
- Cyclin Dependent Kinase Inhibitor p21
- CDKN1 Protein
- Senescent Cell-Derived Inhibitor Protein 1
- Senescent Cell Derived Inhibitor Protein 1
- Cell Cycle Regulator p21
- Cyclin-Dependent Kinase Inhibitor 1A Protein
- Cyclin Dependent Kinase Inhibitor 1A Protein
- Cyclin Kinase Inhibitor p21
- p21 Cyclin Kinase Inhibitor
- CDKN1A Protein
- Cdk-Interacting Protein 1
- Cdk Interacting Protein 1
- Cdk2 Inhibitor Protein
- CDK2-Associated Protein 20 kDa
- CDK2 Associated Protein 20 kDa
- p21 Cell Cycle Regulator
|
Below are MeSH descriptors whose meaning is more general than "Cyclin-Dependent Kinase Inhibitor p21".
Below are MeSH descriptors whose meaning is more specific than "Cyclin-Dependent Kinase Inhibitor p21".
This graph shows the total number of publications written about "Cyclin-Dependent Kinase Inhibitor p21" by people in this website by year, and whether "Cyclin-Dependent Kinase Inhibitor p21" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2005 | 0 | 1 | 1 |
| 2007 | 2 | 3 | 5 |
| 2008 | 2 | 1 | 3 |
| 2010 | 2 | 1 | 3 |
| 2012 | 1 | 0 | 1 |
| 2013 | 0 | 1 | 1 |
| 2021 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Cyclin-Dependent Kinase Inhibitor p21" by people in Profiles.
-
Sequential targeting of YAP1 and p21 enhances the elimination of senescent cells induced by the BET inhibitor JQ1. Cell Death Dis. 2021 Jan 25; 12(1):121.
-
Two 4N cell-cycle arrests contribute to cisplatin-resistance. PLoS One. 2013; 8(4):e59848.
-
The growth response to androgen receptor signaling in ERa-negative human breast cells is dependent on p21 and mediated by MAPK activation. Breast Cancer Res. 2012 Feb 09; 14(1):R27.
-
p53 and p21(Waf1) are recruited to distinct PML-containing nuclear foci in irradiated and Nutlin-3a-treated U2OS cells. J Cell Biochem. 2010 Dec 01; 111(5):1280-90.
-
Persistent p21 expression after Nutlin-3a removal is associated with senescence-like arrest in 4N cells. J Biol Chem. 2010 Jul 23; 285(30):23105-14.
-
Nutlin-3a induces cytoskeletal rearrangement and inhibits the migration and invasion capacity of p53 wild-type cancer cells. Mol Cancer Ther. 2010 Apr; 9(4):895-905.
-
Transient nutlin-3a treatment promotes endoreduplication and the generation of therapy-resistant tetraploid cells. Cancer Res. 2008 Oct 15; 68(20):8260-8.
-
P21 and p27: roles in carcinogenesis and drug resistance. Expert Rev Mol Med. 2008 Jul 01; 10:e19.
-
Geldanamycin promotes premature mitotic entry and micronucleation in irradiated p53/p21 deficient colon carcinoma cells. Oncogene. 2008 Sep 18; 27(42):5567-77.
-
Tamoxifen-stimulated growth of breast cancer due to p21 loss. Proc Natl Acad Sci U S A. 2008 Jan 08; 105(1):288-93.